Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Total Current Liabilities (2021 - 2025)

Rxo (RXO) has disclosed Total Current Liabilities for 5 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities fell 2.54% year-over-year to $1.0 billion, compared with a TTM value of $1.0 billion through Dec 2025, down 2.54%, and an annual FY2025 reading of $1.0 billion, down 2.54% over the prior year.
  • Total Current Liabilities was $1.0 billion for Q4 2025 at Rxo, up from $907.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $1.1 billion in Q4 2024 and bottomed at $662.0 million in Q2 2024.
  • Average Total Current Liabilities over 5 years is $839.5 million, with a median of $823.0 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities dropped 18.02% in 2023, then surged 56.16% in 2024.
  • Year by year, Total Current Liabilities stood at $816.0 million in 2021, then rose by 0.86% to $823.0 million in 2022, then dropped by 17.13% to $682.0 million in 2023, then soared by 56.16% to $1.1 billion in 2024, then dropped by 2.54% to $1.0 billion in 2025.
  • Business Quant data shows Total Current Liabilities for RXO at $1.0 billion in Q4 2025, $907.0 million in Q3 2025, and $880.0 million in Q2 2025.